The combined administration of LNC-encapsulated retinoic acid and calcitriol stimulates oligodendrocyte progenitor cell differentiation in vitro and in vivo after intranasal administration

• Published in: International journal of pharmaceutics 2024-06, Vol.659, p.124237, Article 124237
• Main Authors: Labrak, Y., Alhouayek, M., Mwema, A., d’Auria, L., Ucakar, B., van Pesch, V., Muccioli, G.G., des Rieux, A.
• Format: Article
• Language: English
• Subjects: Lipid nanocapsules; Multiple sclerosis; Oligodendrocyte differentiation; Remyelination; Tretinoin; Vitamin D
• ISSN: 0378-5173; 1873-3476; 1873-3476
• DOI: 10.1016/j.ijpharm.2024.124237

[Display omitted] •Encapsulation in lipid nanocapsules stabilizes retinoic acid.•Combining calcitriol and retinoic acid is more effective than each molecule alone.•Nose-to-brain delivery of calcitriol and retinoic acid enhances myelin repair. Intranasal administration is an efficient strategy for bypassing the BBB, favoring drug accumulation in the brain, and improving its efficiency. Lipid nanocapsules (LNC) are suitable nanocarriers for the delivery of lipophilic drugs via this route and can be used to encapsulate lipophilic molecules such as retinoic acid (RA) and calcitriol (Cal). As the hallmarks of multiple sclerosis (MS) are neuroinflammation and oligodendrocyte loss, our hypothesis was that by combining two molecules known for their pro-differentiating properties, encapsulated in LNC, and delivered by intranasal administration, we would stimulate oligodendrocyte progenitor cells (OPC) differentiation into oligodendrocytes and provide a new pro-remyelinating therapy. LNC loaded with RA (LNC-RA) and Cal (LNC-Cal) were stable for at least 8 weeks. The combination of RA and Cal was more efficient than the molecules alone, encapsulated or not, on OPC differentiation in vitro and decreased microglia cell activation in a dose-dependent manner. After the combined intranasal administration of LNC-RA and LNC-Cal in a mouse cuprizone model of demyelination, increased MBP staining was observed in the corpus callosum. In conclusion, intranasal delivery of lipophilic drugs encapsulated in LNC is a promising strategy for myelinating therapies.